# SNAP-8 (Acetyl Octapeptide-3): Evidence, Mechanism & Status

> A clinical monograph on SNAP-8 (Acetyl Octapeptide-3) — the topical "needle-free Botox" cosmetic peptide. An elongated Argireline with a plausible SNARE-competing mechanism, but only manufacturer claims and one combination-product human trial behind it.

*Published 2026-06-30 · Updated 2026-07-01 · By Marcus Feld, PharmD, BCPS*

The short answer
SNAP-8 (Acetyl Octapeptide-3) is a topical cosmetic peptide — an *elongated Argireline* — that competitively mimics the SNAP-25 N-terminus to mildly and reversibly soften acetylcholine-driven facial micro-contractions. Its mechanism is plausible, but its evidence is weak: the famous "63.13% wrinkle reduction" is an unreplicated manufacturer claim (grade **D**) and the only peer-reviewed human study tested it inside a multi-ingredient microneedle patch (grade **C**). It is a cosmetic ingredient, **not an FDA-approved drug**, and it is **not WADA-prohibited**.[1](https://peptidevox.com/#r1)[8](https://peptidevox.com/#r8)

SNAP-8 (INCI **Acetyl Octapeptide-3**; CAS 868844-74-0) is a synthetic, N-acetylated, C-terminal-amidated octapeptide developed by Lipotec (now Lubrizol Life Science) and marketed as a topical "needle-free Botox-alternative" cosmetic active.[3](https://peptidevox.com/#r3) Its popularity in anti-aging skincare is large; its independent proof is not. This monograph separates the two.

*This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing or buying guide. SNAP-8 is a topical cosmetic ingredient, not a drug; nothing here should be read as guidance to inject, ingest, or use it off-label. Dosing and use levels are reported strictly as seen in the cosmetic literature and manufacturer dossiers for completeness. Consult a qualified clinician or dermatologist before acting on anything herein.*

## What is SNAP-8 and how does it work?

SNAP-8 is the cosmetic peptide Acetyl Octapeptide-3 (also marketed as Acetyl Glutamyl Heptapeptide-1; trade name SNAP-8). Its sequence is Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2 — one-letter **Ac-EEMQRRAD-NH2** — with a molecular weight of roughly 1075 g/mol.[3](https://peptidevox.com/#r3)[4](https://peptidevox.com/#r4) Chemically it is simply Argireline (Ac-EEMQRR-NH2, acetyl hexapeptide-8, MW about 889 Da) extended by two residues, alanine and aspartate. The shared **EEMQRR** core is the functional SNAP-25 mimic; the two extra residues are claimed to improve binding geometry and stability.[2](https://peptidevox.com/#r2)[3](https://peptidevox.com/#r3)

The mechanism centers on SNARE-complex competition. Facial-expression muscle contraction requires acetylcholine release at the neuromuscular junction, driven by vesicle fusion via the SNARE complex — the ternary VAMP-syntaxin-SNAP-25 assembly. SNAP-8 reproduces the N-terminal domain of SNAP-25 and competes with native SNAP-25 for incorporation into the nascent complex; the resulting "defective" complex docks vesicles less efficiently, attenuating acetylcholine exocytosis and softening the repetitive micro-contractions that etch dynamic lines.[2](https://peptidevox.com/#r2)[1](https://peptidevox.com/#r1) This is the same target pathway as botulinum toxin but a fundamentally different action: Botox is an enzyme that *irreversibly cleaves* SNAP-25 (profound, prolonged chemodenervation at roughly nanogram-per-kilogram potency by injection), whereas SNAP-8 merely *crowds it out* competitively — a mild, reversible, non-paralytic effect, with the peptide class showing acute toxicity at or above 2000 mg/kg versus about 20 ng/kg for Botox.[2](https://peptidevox.com/#r2)

The defining pharmacodynamic limitation is poor skin permeation. Like Argireline, SNAP-8 is large (MW about 1075 Da, above the roughly 500 Da "rule" for passive stratum-corneum penetration) and highly hydrophilic. For Argireline, only about 0.22% of applied peptide was retained in the stratum corneum and about 0.01% reached the epidermis; SNAP-8, being larger and more polar, is expected to permeate no better and likely worse.[2](https://peptidevox.com/#r2) Because so little peptide crosses intact skin, systemic exposure from cosmetic use is considered negligible, and delivery vehicles such as microneedles are studied to overcome the barrier.[6](https://peptidevox.com/#r6) There are no human pharmacokinetic data — no established plasma half-life, Cmax, or clearance.

## What is the evidence by indication?

The single best-evidenced use is purely cosmetic: reducing the appearance of *dynamic* expression wrinkles such as crow's feet, forehead lines and the glabella. The human-relevant evidence is two-tiered and weak, summarized below.

  SNAP-8 evidence by source tier

    SourceWhat it showsGrade

    Lipotec/Lubrizol manufacturer dossierUp to 63.13% periorbital wrinkle-depth reduction at 28 days (10% twice daily); small, not peer-reviewed, not replicatedD (manufacturer claim)
    Shin et al., Annals of Dermatology 20240.03% SNAP-8 inside a multi-ingredient dissolving microneedle patch; significant wrinkle/roughness gains, contribution not isolableC (combination product)
    SNAP-8 monotherapy RCT (independent)Does not exist — no published placebo-controlled trial of SNAP-8 as a single agentNone
    Argireline analog (for calibration)Manufacturer RCT positive; independent rebuttal found no significant effectB-to-D (contested)

The ubiquitous headline figure — up to 63.13% reduction in crow's-feet wrinkle depth after 28 days of twice-daily 10% SNAP-8 — derives from Lipotec's proprietary technical dossier, reportedly a small in-vivo study (commonly cited as around 17 female volunteers) using silicone-replica profilometry, not a peer-reviewed independent RCT.[8](https://peptidevox.com/#r8) Companion vendor claims (about 21% reduction at 7 days; "30% more active than Argireline") share the same low-grade, manufacturer-funded provenance, and independent commentary notes real-world results are likely far more modest, often in the 10-20% range.[6](https://peptidevox.com/#r6) Treat 63% as a marketing benchmark, not a validated clinical effect.

The one indexed clinical study is Shin et al., *Annals of Dermatology* 2024 — a split-face evaluation of a dissolving microneedle patch containing 0.03% SNAP-8 *plus* 5% AA2G (vitamin-C derivative), niacinamide-class actives and 90% hyaluronic acid. In 24 enrolled and 21 completing subjects over 28 days, the patch produced statistically significant improvements versus a placebo HA-only patch: a significant decrease in deep-wrinkle proxies (including after a single 2-hour application), significant roughness-parameter decreases at days 7-28, and significantly better eye-lifting at day 14 — with no adverse events.[1](https://peptidevox.com/#r1) The critical limitation is that this is a multi-ingredient, microneedle-delivered formulation: SNAP-8's individual contribution cannot be isolated from the vitamin-C, niacinamide-class and HA components, nor from the mechanical microneedling effect. The trial is registered in the family of dermatology studies indexed at [the U.S. National Library of Medicine's PMC archive](https://pmc.ncbi.nlm.nih.gov/articles/PMC11291098/); readers can verify its design and limitations there directly.

For calibration, the closest analog — Argireline — is itself contested. A manufacturer-aligned RCT (n=60, 10% acetyl hexapeptide-8 twice daily for four weeks) reported roughly 48-49% periorbital wrinkle reduction, but it was manufacturer-funded.[5](https://peptidevox.com/#r5) A later independent evaluation found no statistically significant wrinkle reduction and concluded the peptide "is not deemed to be an alternative treatment to botulinum toxin."[7](https://peptidevox.com/#r7) Because the "30% more active than Argireline" claim builds on a parent peptide whose own efficacy is unconfirmed, SNAP-8's superiority claim is doubly unverified.[6](https://peptidevox.com/#r6)

Proven vs hyped
Proven: SNAP-8 is safe and well tolerated topically, and a SNAP-8-*containing* microneedle patch improved wrinkle and roughness metrics (grade C for SNAP-8's role). Hyped: the famous 63.13% figure and the "30% better than Argireline" line are manufacturer claims (grade D), unreplicated and undercut by poor skin permeation — and even Argireline failed independent replication.[8](https://peptidevox.com/#r8)[6](https://peptidevox.com/#r6)

## What doses appear in the literature, and how safe is it?

Reported strictly as information, not a protocol. SNAP-8 is topical-only in cosmetic practice; there is no legitimate clinical use as an injectable or systemic agent.[3](https://peptidevox.com/#r3) Finished-product formulations typically incorporate about 2-10% of a *pre-diluted* SNAP-8 solution, meaning the actual peptide concentration is well below the headline percentage.[10](https://peptidevox.com/#r10) The manufacturer's headline regimen is 10% SNAP-8 cream applied twice daily for 28 days to periorbital lines, while the clinical microneedle regimen used 0.03% SNAP-8 within the patch.[9](https://peptidevox.com/#r9)[1](https://peptidevox.com/#r1) It is supplied as a 2-5% aqueous or glycol pre-dissolved solution, stable at roughly pH 5-7. Vendor data suggest gradual improvement over weeks; it is not a Botox equivalent and does nothing for static wrinkles, deep folds or volume loss.[8](https://peptidevox.com/#r8)

On safety, SNAP-8 is regarded as well tolerated topically. The 28-day microneedle trial reported no adverse events across repeated same-site use, with transepidermal water loss decreasing rather than increasing.[1](https://peptidevox.com/#r1) The most common reported issue is occasional mild irritation or redness in sensitive individuals, which should prompt discontinuation.[11](https://peptidevox.com/#r11) Systemic risk is negligible because so little peptide crosses intact skin, and the parent peptide class shows very low acute toxicity.[2](https://peptidevox.com/#r2) Reasonable cautions include known hypersensitivity, application to broken or inflamed skin, and pregnancy or lactation, where no controlled data exist.[11](https://peptidevox.com/#r11) A functional caveat: the realistic expectation is cosmetic surface softening of dynamic lines, not correction of the underlying drivers of skin aging — collagen loss, glycation, photodamage and oxidative load — so SNAP-8 is best contextualized within sun protection and broader skin-health fundamentals rather than treated as a standalone anti-aging solution.

## What is the FDA and WADA status in 2026?

SNAP-8 is not an FDA-approved drug and has not been submitted for drug approval. When used topically to affect appearance it is regulated as a cosmetic ingredient under the INCI name Acetyl Octapeptide-3, and cosmetic ingredients other than color additives require no premarket FDA approval.[14](https://peptidevox.com/#r14) A claim caveat applies: because the marketed mechanism is a physiological neuromuscular effect, aggressive "relaxes muscles" or "Botox-alternative" claims can cross into drug claims and trigger FDA drug-misbranding concerns — a genuine regulatory gray zone for the category.[14](https://peptidevox.com/#r14) It is recognized as a cosmetic ingredient in the EU, Japan, Canada and Australia, with no major regulator issuing safety communications specific to acetyl octapeptide-3 as of 2026.[12](https://peptidevox.com/#r12) Separately, a "research chemical, not for human use" market sells unverified SNAP-8 outside the cosmetic channel; this monograph does not endorse that use.[13](https://peptidevox.com/#r13) SNAP-8 is not a DEA controlled substance.

For athletes the picture is straightforward. SNAP-8 is not on the WADA Prohibited List; as a topical cosmetic neuromodulating peptide with no anabolic, hormone-secretagogue or oxygen-transport activity, it does not fall within any current prohibited class.[15](https://peptidevox.com/#r15) Because peptide classifications evolve, any tested athlete should still verify the current list before use.

**Bottom line.** SNAP-8 is a mechanistically coherent topical cosmetic peptide — an elongated Argireline that competitively softens acetylcholine-driven facial micro-contractions, the same target as botulinum toxin but a vastly milder, non-paralytic, non-injectable action. It has been studied in small numbers of adult women through a manufacturer dossier and one 21-completer combination-microneedle trial. It is safe and well tolerated topically, but its dramatic vendor numbers should be heavily discounted: no independent monotherapy RCT exists, the effect size through intact skin is unknown and likely small, and there are no human pharmacokinetic data. It is a legitimate, low-risk cosmetic active with plausible-but-unproven topical efficacy — not a Botox substitute, not a drug, and not banned in sport. Overall evidence grade: C-D.

---
Source: https://peptidevox.com/peptide-encyclopedia/snap-8
Index: https://peptidevox.com/llms.txt · Full text: https://peptidevox.com/llms-full.txt